WraSer Pharmaceuticals, LLC Launches Instant Rebate Programs
June 1, 2010
For Immediate Release
WraSer Pharmaceuticals, LLC Announces the launch of two new Instant Rebate programs to assist in patients’ out-of-pocket costs of prescription Cetraxal® and Xolox™.
Ridgeland, MS (June 1, 2010) – WraSer Pharmaceuticals, LLC (WraSer) announced today that it has launched two individual instant rebate programs for prescription Cetraxal® and Xolox™ to assist in patients’ out-of-pocket costs.
Cetraxal® received final FDA approval in May 2009 and is the first and only single agent ciprofloxacin otic available in the United States. The product contains ciprofloxacin otic solution 0.2%, representing a safe and effective therapy for the treatment of acute otitis externa due to isolates of Pseudomonas aeruginosa and Staphylococcus aureus. Physicians have few fluoroquinolone otic alternatives in prescribing, especially treatment options that offer such a simple unique dosing system that is both fast and effective for any caregiver. Cetraxal® fills this important niche in the market for effective otic-management treatments.
“WraSer is pleased to offer for the first time these instant rebate programs for both Cetraxal® and Xolox™ that will aid in the cost of our patients’ out-of-pocket expenses instantly,” said Ford Mundy, Product Manager for WraSer. “WraSer is always looking to provide cost effective treatment options to the physicians and patients we serve. Instant Rebates for Cetraxal® and Xolox™ are a great complement to our current and growing set of offerings in these markets.”
Cetraxal® and Xolox are available immediately to retail pharmacies and wholesale pharmacy distribution channels. Cetraxal® and Xolox™ are available by prescription only. For full prescribing information, please contact WraSer Pharmaceuticals, LLC at the contact number listed below.
About WraSer Pharmaceuticals, LLC
WraSer is a privately held specialty pharmaceutical company headquartered in Ridgeland, MS. The Company actively markets prescription pharmaceutical products focused on primary care, pediatric, pain management, and dermatological markets. WraSer markets its products through its proprietary sales force. The Company is continually expanding its product portfolio through direct development and FDA submissions, partnerships and in-licensing agreements. Further information regarding WraSer is available at www.wraser.com.
For Information Please Contact:
Cetraxal® is a registered trademark of Laboratorios Salvat, S.A
Posted on 6/1/2010
View All Postings